Clinical Trials Browser

Phase 1/2 × Ramucirumab × 90 days × Clear all

NCT06445972 2026-03-16

MK-3475-06D

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06996782 2026-02-24

ALTAIR

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06007937 2026-02-05

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Solid Cancer

NCT03008278 2026-02-03

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Phase 1/2 Completed

51 enrolled 20 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03650764 2025-12-30

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck